Pediatrics Department, University Hospital of Foggia, Foggia, Italy.
IDESP, UA11-INSERM, University of Montpellier, Montpellier, France.
Ital J Pediatr. 2024 Sep 27;50(1):194. doi: 10.1186/s13052-024-01758-y.
Multisystem Inflammatory Syndrome in Children (MIS-C) is a rare complication, which develops within 3-6 weeks after SARS-CoV2 infection. The coronavirus disease 2019 (COVID-19) vaccine was firstly introduced in adults and adolescents and later in patients aged 5-11 years old. Although a reduced incidence of MIS-C and with less severe symptoms has been reported in vaccinated adolescents, there is little knowledge in children younger than 12 years of age. In addition, it is not understood whether MIS-C in vaccinated patients can be triggered by Covid19 vaccination or be secondary to a recent asymptomatic Sars-Cov2 infection.
We describe the case of a Caucasian 6-year-old girl, one month after double COVID-19 vaccination, who presented fever, acute abdominal pain, rash, pharyngotonsillitis, cheilitis, cervical lymphadenopathy without a prior detected Sars-Cov2 infection. She also had lymphopenia, increase in inflammatory markers, cardiac and pulmonary involvement. Therefore, we dosed both anti Sars-Cov2 Spike and Nucleocapsid antibodies, which were positive and allowed us to confirm the diagnosis of MIS-C. We promptly administered intravenous immunoglobulins and methylprednisone, resulting in the initial regression of fever. During the hospitalization, the child also developed pancreatitis and severe neurological involvement, including irritability, drowsiness, distal tremor, dyskinesia and buccal asymmetry with complete resolution after 2 months. After 3 months from the onset of the symptoms, she reported a transient loss of hair compatible with telogen effluvium. After 12 months of follow-up, she did not show any symptomatic sequelae.
This case raises the question of whether COVID-19 vaccination may be involved in the pathogenesis of MIS-C in children between the ages of 5 and 11 years old.
儿童多系统炎症综合征(MIS-C)是一种罕见的并发症,在 SARS-CoV2 感染后 3-6 周内发展。新型冠状病毒病 2019(COVID-19)疫苗最初在成年人和青少年中使用,后来在 5-11 岁的患者中使用。尽管接种疫苗的青少年报告的 MIS-C 发病率降低且症状较轻,但对于 12 岁以下的儿童知之甚少。此外,尚不清楚接种疫苗的患者中 MIS-C 是由 COVID19 疫苗引发的,还是继发于最近无症状的 SARS-CoV2 感染。
我们描述了一名高加索裔 6 岁女孩的病例,她在双价 COVID-19 疫苗接种后一个月,出现发热、急性腹痛、皮疹、咽扁桃体炎、唇炎、颈部淋巴结肿大,此前未检出 SARS-CoV2 感染。她还伴有淋巴细胞减少、炎症标志物升高、心脏和肺部受累。因此,我们检测了抗 SARS-CoV2 刺突蛋白和核衣壳蛋白抗体,均为阳性,从而确诊了 MIS-C。我们立即给予静脉注射免疫球蛋白和甲基强的松龙,使发热最初得到缓解。住院期间,患儿还出现了胰腺炎和严重的神经系统受累,包括易激惹、嗜睡、远端震颤、运动障碍和口轮匝肌不对称,2 个月后完全缓解。症状发作后 3 个月,她出现了一过性脱发,符合休止期脱发。症状发作后 12 个月,她没有出现任何有症状的后遗症。
该病例提出了 COVID-19 疫苗是否可能参与 5-11 岁儿童 MIS-C 发病机制的问题。